Bookmark and Share
blaVIM-2 (geneid:14678525) - Gene BioActivity Data
Also known as: D703_p16.
BioActivity Outcomes:
Probe(6)
 
 
Active(4354)
 
 
Inactive(289584)
 
 
Inconclusive(8)
 
 
Unspecified(108)
 
 
BioAssay Types:
Screening(293423)
 
 
 
Confirmatory(351)
 
 
 
 
Literature(131)
 
 
 
 
Summary(1)
 
 
BioActivity Types:
IC50(348)
 
 
 
 
Ki(3)
 
 
 
 
Substance Types:
Chemical(294060)
 
 
 
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 33    Data Row: 294060   Total Pages: 5882   Display: Page     
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID134220672]
[CID53362017]
Ki 0.183Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624083, Type: confirmatory] [gi:7381449]
View
2
[SID134220672]
[CID53362017]
MIC [4 fold reduction] 0.391Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
3
[SID125264855]
[CID53362017]
IC50 0.5481Late stage assay provider results from the probe development efforts to identify nonselective inhibitors of VIM-2 metallo-beta-lactamase: Absorbance-based biochemical assays to determine the ability of probe candidates and selected analogs to inhibit VIM-2 [AID624079, Type: confirmatory] [gi:7381449]
View
4
[SID125264855]
[CID53362017]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
5
[SID125264855]
[CID53362017]
MIC [4 fold reduction] 3.125Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): VIM-2-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624081, Type: other] [gi:7381449]
View
6
[SID85856282]
[CID4870494]
Summary of probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase [AID1854, Type: summary] [gi:7381449]
View
7
[SID24790728]
[CID4870494]
IC50 0.03394FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
8
[SID24790728]
[CID4870494]
IC50 0.05435Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
9
[SID24707842]
[CID11834391]
IC50 0.12018FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
10
[SID135383770]
[CID56851709]
MIC [4 fold reduction] 0.195Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
11
[SID85856282]
[CID4870494]
0.223Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: probe results [AID2128_2, Type: other] [gi:7381449]
View
12
[SID26666672]
[CID302501]
IC50 0.24479FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
13
[SID92192479]
[CID45105307]
IC50 0.2454Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of VIM-2 metallo-beta-lactamase [AID2769, Type: confirmatory] [gi:7381449]
View
14
[SID47197611]
[CID6863594]
IC50 0.33229FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
15
[SID24837288]
[CID9643280]
IC50 0.33463FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
16
[SID26671366]
[CID1547995]
IC50 0.37361FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
17
[SID49679995]
[CID2818392]
IC50 0.37422Epi-absorbance-based dose response assay for common IMP-1 and VIM-2 inhibitors: biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase [AID2754, Type: confirmatory] [gi:7381449]
View
18
[SID49668006]
[CID1427313]
IC50 0.43308FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
19
[SID24707842]
[CID11834391]
IC50 0.45301Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
20
[SID49822987]
[CID16406937]
IC50 0.525FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
21
[SID14731782]
[CID1312855]
IC50 0.582FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
22
[SID85856281]
[CID4212]
0.63Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results [AID2317_2, Type: screening] [gi:7381449]
View
23
[SID864455]
[CID279160]
IC50 0.689FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
24
[SID49816141]
[CID2951249]
IC50 0.7FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
25
[SID26671514]
[CID1418929]
IC50 0.716FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
26
[SID26666672]
[CID302501]
IC50 0.748Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
27
[SID24817912]
[CID1482500]
IC50 0.774FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
28
[SID125264857]
[CID53362007]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): VIM-2-transformed E. coli growth inhibition in the presence of imipenem (synergy) [AID624081, Type: other] [gi:7381449]
View
29
[SID134220673]
[CID54579797]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
30
[SID134220676]
[CID53384679]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
31
[SID126723255]
[CID53495083]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
32
[SID131269026]
[CID54579799]
MIC [4 fold reduction] 0.781Late stage assay provider results from the probe development efforts to identify inhibitors of VIM-2 metallo-beta-lactamase (nonselective): Growth inhibition of clinically relevant VIM-2-transformed Acinetobacter species (YMC07/8/B3323) in the presence of imipenem (synergy) [AID624096, Type: other] [gi:7381449]
View
33
[SID92192478]
[CID45105304]
IC50 0.8137Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of VIM-2 metallo-beta-lactamase [AID2769, Type: confirmatory] [gi:7381449]
View
34
[SID92192482]
[CID45105306]
IC50 0.81718Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of VIM-2 metallo-beta-lactamase [AID2769, Type: confirmatory] [gi:7381449]
View
35
[SID4251926]
[CID3245548]
IC50 0.862FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
36
[SID14727309]
[CID3220530]
IC50 0.874FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
37
[SID24823360]
[CID56642947]
IC50 0.885FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
38
[SID24827984]
[CID2383141]
IC50 0.889FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
39
[SID26659839]
[CID776411]
IC50 0.89428Epi-absorbance-based dose response assay for common IMP-1 and VIM-2 inhibitors: biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase [AID2754, Type: confirmatory] [gi:7381449]
View
40
[SID24837963]
[CID2478591]
IC50 0.94FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
41
[SID860535]
[CID5389373]
IC50 0.941FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
42
[SID24797434]
[CID1768080]
IC50 0.961FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
43
[SID92192480]
[CID10448266]
IC50 1.001Late stage results from the probe development effort to identify common IMP-1 and VIM-2 inhibitors: Epi-absorbance-based biochemical dose response assay for inhibitors of VIM-2 metallo-beta-lactamase [AID2769, Type: confirmatory] [gi:7381449]
View
44
[SID24837288]
[CID9643280]
IC50 1.004Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
45
[SID51090312]
[CID7190975]
IC50 1.116FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
46
[SID24823265]
[CID44601849]
IC50 1.161FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
47
[SID17402883]
[CID1482495]
IC50 1.202FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View
48
[SID47197611]
[CID6863594]
IC50 1.229Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
49
[SID26671366]
[CID1547995]
IC50 1.293Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase [AID1919, Type: confirmatory] [gi:7381449]
View
50
[SID26729856]
[CID2816425]
IC50 1.31FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. [AID1926, Type: confirmatory] [gi:7381449]
View